As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
admin 5th December 2017 Uncategorised 0Johnson & Johnson’s blockbuster anti-TNF drug Remicade fell victim to biosimilar competition in Europe in 2015 and in the U.S. last year, but the impact of the inexpensive copycat drugs has been quite different in the two regions.
More: As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Source: fierce